Cyclerion Therapeutics
CYCN
17 hedge funds and large institutions have $3.66M invested in Cyclerion Therapeutics in 2023 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 4 reducing their positions, and 3 closing their positions.
3.02% more ownership
Funds ownership: 41.5% → 44.52% (+3%)
6% less funds holding
Funds holding: 18 → 17 (-1)
11% less capital invested
Capital invested by funds: $4.1M → $3.66M (-$438K)
25% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 4
33% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$3.7K |
| 2 |
Osaic Holdings
Scottsdale,
Arizona
|
+$678 |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$324 |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$263 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$147K |
| 2 |
CAPTRUST Financial Advisors
Raleigh,
North Carolina
|
-$60.3K |
| 3 |
Jane Street
New York
|
-$55.1K |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
-$11.5K |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.44K |
CYCN Hedge Fund Activity: Q3 2023 in Review
17 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Cyclerion Therapeutics (CYCN) for Q3 2023, worth a combined $3.66M — down 11% from $4.1M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of CYCN and 2 opened new positions — a net loss of 1 holder — while 4 trimmed existing stakes and 3 added.
The largest buyer was Geode Capital Management, adding an estimated $3.7K. The largest seller was Vanguard Group, cutting an estimated $147K.
- 17 institutional investors held Cyclerion Therapeutics (CYCN) as of Q3 2023, down from 18 in Q2 2023.
- Funds reported $3.66M of Cyclerion Therapeutics stock for Q3 2023, down 11% quarter-over-quarter.
- 2 funds opened new Cyclerion Therapeutics positions in Q3 2023 and 3 closed out, a net change of -1 holder.
- The largest Cyclerion Therapeutics buyer in Q3 2023 was Geode Capital Management, an estimated $3.7K added.
- The largest Cyclerion Therapeutics seller in Q3 2023 was Vanguard Group, an estimated $147K sold.
Based on aggregated 13F filings for Q3 2023.